SCHEMBL9892852

SCHEMBL9892852

O=C(Nc1nc(-c2ccccc2)cs1)[C@@H]1CCN1C1CCOCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.58
SMN1; SMN2 Q16637 7/20 0.57
ALDH1A1 P00352 5/20 0.57
NPC1 O15118 2/20 0.57
ELOVL1 Q9BW60 1/20 0.57
LMNA P02545 6/20 0.56
MAPT P10636 5/20 0.56
USP2 O75604 2/20 0.56
HSD17B10 Q99714 1/20 0.56
HTT P42858 3/20 0.55
KDM4E B2RXH2 2/20 0.55
RAB9A P51151 2/20 0.53
NPSR1 Q6W5P4 3/20 0.52
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
RAF1 P04049 1/20 0.49
MAPK1 P28482 1/20 0.49
CNR1 P21554 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13256841 0.93 SMN1; SMN2 (0.63) CNR2SMN1; SMN2ALDH1A1NPC1ELOVL1
SCHEMBL9892823 0.86 RAB9A (0.54) CNR2SMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL9892822 0.81 TP53 (0.56) CNR2SMN1; SMN2NPC1LMNAHSD17B10
SCHEMBL9892825 0.80 CNR2 (0.50) CNR2SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL9892847 0.79 CNR2 (0.65) CNR2SMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL9892794 0.78 CNR2 (0.62) CNR2SMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL13256788 0.78 SMN1; SMN2 (0.60) CNR2SMN1; SMN2ALDH1A1NPC1ELOVL1
SCHEMBL9891546 0.78 CNR2 (0.47) CNR2SMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL9892792 0.77 ALDH1A1 (0.62) CNR2ALDH1A1MAPTHSD17B10NPSR1
SCHEMBL9374001 0.76 LMNA (0.78) CNR2SMN1; SMN2ALDH1A1NPC1ELOVL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 CNR2 1/4885SMN1; SMN2 4282/4885ALDH1A1 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.